XORTX Therapeutics Inc. (XRTX)
Nasdaq · Healthcare · Biotechnology
$1.70−0.83%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.1M
- Forward P/E
- 2.1
- 52-week range
- $1.59 – $7.05
- 52-week change
- −62.12%
- EPS (trailing)
- −$2.61
- Next earnings
- Nov 12, 2026
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Headquarters: Calgary, Canada · xortx.com